AHL
ALLO icon

Abel Hall LLC’s Allogene Therapeutics ALLO Stock Holding History

Abel Hall LLC’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.8K Sell
26,348
-299
-1% -$657 0.01% 895
2026
Q1 		$65K Buy
26,647
+9,604
+56% +$19.3K 0.01% 723
2025
Q4 		$23.3K Buy
+17,043
New +$22.5K 0.01% 696

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Abel Hall LLC's ALLO Position: Q2 2026 in Review

Abel Hall LLC reduced its Allogene Therapeutics (ALLO) stake by 1.1% in Q2 2026, selling an estimated $657 and leaving 26,348 shares worth $54.8K. The position accounts for 0.01% of the portfolio, ranked #895.

Abel Hall LLC first reported a position in ALLO in Q4 2025 and has held it in 3 quarters since. The position peaked at $65K in Q1 2026. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Abel Hall LLC held 26,348 shares of Allogene Therapeutics worth $54.8K as of Q2 2026.
  • Abel Hall LLC sold 299 Allogene Therapeutics shares in Q2 2026, an estimated $657.
  • Allogene Therapeutics made up 0.01% of Abel Hall LLC's portfolio in Q2 2026, its #895 holding.
  • Abel Hall LLC first reported a position in Allogene Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Abel Hall LLC's Allogene Therapeutics position peaked at $65K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.